E01P0585 Human Pituitary adenylate cyclase activating polypeptide ELISA kit
The Human Pituitary adenylate cyclase activating polypeptide ELISA kit can be used to identify samples from the human species. Pituitary adenylate cyclase activating polypeptide can also be called PACAP, ADCYAP1, PRP-48, Pituitary Adenylate Cyclase Activating Peptide, adenylate cyclase activating polypeptide 1.
Product Information | |
Cat. No. | E01P0585 |
Product Name | Human Pituitary adenylate cyclase activating polypeptide ELISA kit |
Species | Human |
Product Size | 48 Tests / 96 Tests |
Concentration | 50-1000 pg/ml |
Sensitivity | 1.0 pg/ml |
Principal | Competitive ELISA |
Sample Volume | 100 ul |
Sample Type | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate |
Assay Time | 90 minutes |
Platform | Microplate Reader |
Conjugate | HRP |
Detection Method | Colorimetric |
Storage | 2-8°C |
Kit Components | ||
MATERIALS | SPECIFICATION | QUANTITY |
MICROTITER PLATE | 96 wells | stripwell |
ENZYME CONJUGATE | 6.0 mL | 1 vial |
STANDARD A (0.5mL) | 0 pg/mL | 1 vial |
STANDARD B (0.5mL) | 50 pg/mL | 1 vial |
STANDARD C (0.5mL) | 100 pg/mL | 1 vial |
STANDARD D (0.5mL) | 250 pg/mL | 1 vial |
STANDARD E (0.5mL) | 500 pg/mL | 1 vial |
STANDARD F (0.5mL) | 1000 pg/mL | 1 vial |
SUBSTRATE A | 6 mL | 1 vial |
SUBSTRATE B | 6 mL | 1 vial |
STOP SOLUTION | 6 mL | 1 vial |
WASH SOLUTION (100 x) | 10 mL | 1 vial |
BALANCE SOLUTION | 3 mL | 1 vial |
Principle of the Assay |
PACAP ELISA kit uses an anti-PACAP antibody and a PACAP-HRP conjugate in a competitive enzyme immunoassay method. PACAP-HRP conjugate is incubated with the assay sample and buffer in a pre-coated plate for one hour. The wells are decanted and washed five times when the incubation period is over. The HRP enzyme substrate is then incubated in the wells. The result of the enzyme-substrate reaction is a complex that is blue in hue. The process is finally stopped by adding a stop solution, causing the solution to turn yellow. In a microplate reader, the color intensity is measured spectrophotometrically at 450 nm. Due to competition for the anti-PACAP antibody binding site between PACAP from samples and PACAP-HRP conjugate, the intensity of the color is inversely proportional to the concentration of PACAP. Since the number of sites is limited, as more sites are occupied by PACAP from the sample, fewer sites are left to bind PACAP-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The PACAP concentration in each sample is interpolated from this standard curve. |
Coefficient of Variance | Intra Variation% ＜10% | |
Inter Variation% ＜12% | ||
Recovery | 95-102% | |
Linearity | Diluent Ratio | Range % |
1:2 | 93-105 | |
1:4 | 88-106 | |
1:8 | 86-108 | |
Specificity/Cross-reactivity | No significant cross-reactivity or interference between PACAP and analogues was observed. | |
E01P0585 has been referenced in the below publications：
No Change in Interictal PACAP Levels in Peripheral Blood in Women With Chronic Migraine.
Is it useful to determine CGRP, VIP, and PACAP in migraine? A cross-sectional study in chronic migraine patients.
Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.
Related Bluegene Biotech Products
